Viome Dx

08/04/2022

Viome Life Sciences Unveils CancerDetect™, the Future of Oral and Throat Cancer Detection

CancerDetect™ brings unprecedented accuracy to early cancer detection and prevention as the only oral and throat cancer test to offer detection with 95% specificity and 90% sensitivity. Oral and throat cancer is notoriously difficult to detect.

Until now, it can often go undiagnosed until it has reached an advanced stage due to a lack of effective diagnostics tools, leading to low survival rates. Only 28% of patients receive an early diagnosis, and those receiving a late diagnosis face a prolonged battle with oral cancer. (National Library of Medicine).

Early detection directly increases the 5-year survival rate for oral cancer patients, from 50% to 84%. With CancerDetect™, Viome has developed a much-needed aid to detect early-stage cancer, leading to more successful treatment outcomes when confirmed with a biopsy.

***Disclaimer***
Viome's CancerDetect Test is not an FDA-approved or cleared test.

08/04/2022

In 2016 we founded Viome with a mission to make illness optional and bring our cutting-edge science and technology directly to individuals with advanced at-home testing. This includes returning the benefits of our discoveries to our users and being able to expand our testing capabilities even further.

We are happy to announce that the revolutionary mRNA technology and AI-powered platform behind our Intelligence™ Tests for precise food recommendations and supplements have paved the way for our line of Discovery™ Tests, which includes a series of diagnostic tests in development!

Today, we celebrate the launch of CancerDetect™ for Oral & Throat Cancer.

This test is the first to detect biomarkers for early-stage oral and throat cancers based on technology that has received FDA Breakthrough Device Designation. CancerDetect™ brings unprecedented accuracy to early cancer detection and prevention as the only oral and throat cancer test to offer detection with 95% specificity and 90% sensitivity.

CancerDetect™ is available to individuals at higher risk of developing these cancers, fulfilling an unmet need for advanced, earlier detection when it is most easy to treat. If detected early, these cancers can be treated and likely increase 5-year survival to 84% (compared to less than 50% without).

In addition to head and neck cancers, Viome has an extensive ongoing clinical study pipeline in gastrointestinal cancers, including colorectal cancer, pancreatic, ovarian, cervical, and biliary cancers. We currently have cancer research trials that use saliva, blood, stool, and tumor biopsies to understand the onset and progression of cancer. By identifying the biomarkers that lead to the development of cancers, Viome can optimize early detection and identify the right therapeutic targets.

Thank you to everyone at Viome that made this possible and our external academic partners!

https://lnkd.in/gdY7vaKR

04/12/2022

"Guruduth Banavar is a leader in Artificial Intelligence known for his work on Host/Microbe Molecular Data Analysis, IBM Watson AI Systems, Smarter Cities, Services Innovation, Mobile Computing, and Distributed Systems. As founding CTO at Viome Life Sciences, Guruduth leads AI and co-leads clinical research. His role encompasses clinical research, epidemiology, machine learning, computational biology, bioinformatics as well as data and software architecture and development."

In this episode, Guru will discuss:

-His background and journey to Viome
-Viome's mission and work with chronic diseases
-The role of AI, ML, and Biology in achieving our mission
-What excites him for the future at Viome

Guruduth Banavar, Founding CTO and Head of Discovery at Viome joins host JP Valentine on the AI in Action podcast to discuss Viome's mission and work they do within chronic diseases, the role of AI,…

04/05/2022

Naveen Jain, Founder of Viome Life Sciences, debuts as Neurohacker Collective guest host, along with Viome Life Scieces' Global Head of R&D, Dr. Emmanuel Hanon, taking us on a thrilling discussion of how gut microbiome research is shaping the future of disease prevention and longevity. We dive deep into the bilateral connection between the gut and the brain, unpacking:

-The role of the gut-brain axis and gene expression in disease prevention
-How the gut microbiome informs the immune system
-The fascinating relationship between the microbiome, neuromodulation, and mood

"There is a bilateral connection between your gut and your brain and the information circulates through the parasympathetic, sympathetic nerve, and vagus nerve." - Emmanuel Hanon, Ph.D.

We have a Collective Insights first for you! Today Naveen Jain, Founder of Viome, debuts as our guest host, along with fellow colleague Dr. Hanon, taking us on a thrilling discussion of how gut microbiome research is shaping the future of disease prevention and longevity. We dive deep into the bilat...

03/24/2022

“The gut microbiome’s key functions are all related to metabolism, immune system education and regulation, and protection against pathogen invasion. This study will help us understand not only how the gut microbiome changes within the individual as they undergo immunotherapy, but also how it differs among patients throughout the course of their treatment. - AdventHealth Cancer Institute gynecologic oncologist Nathalie D. McKenzie, MD.

This study is part of a collaboration with Viome Life Sciences, a systems biology and artificial intelligence company working to develop next generation of diagnostics and therapeutics to detect disease earlier and improve treatment.

“From the specimens, we can generate vast amounts of molecular data relevant to chronic diseases and cancers,” said Momchilo (Momo) Vuyisich, PhD, Viome Life Sciences Chief Science Officer. “Machine learning and artificial intelligence then makes sense of the data and translates the findings into clinically useful diagnostics and therapeutics.”

AdventHealth Cancer Institute gynecologic oncologist Nathalie D.

03/08/2022

“For girls and boys alike, I hope that opportunities will become attainable for all students to participate in this wonderful program. Gender has no place in science. The only thing that matters in science are facts.”

-Anél Visser, Director Clinical & Diagnostic Laboratory Operations at Viome

Getting to know Anél:

Q: What excites you most about working at Viome?

A: “Knowing that I work for open minded forward thinking people whose main goal is not to make money but to create a health and wellness maintenance system that is cost efficient, doable, scientifically based that the world could benefit by, is truly what motivates and excites me daily.
The other fantastic experience here at Viome is that my job is not a 8-4 or a 9-5 job that I go to and then leave to go home. This is a constant lifestyle and mindset commitment without time restrictions. I live what I work ... It is my daily commitment, whether at home or in my lab and in my office.”

Q: How do you describe the work that you do?

A: “My specific job is very data quality driven, and to create systems and platforms where client samples can be analyzed using very unique biochemical-scientific methods, and then examine all the analytical information derived from those patient samples. The final goal is to improve on methods so that the most accurate and most informative data can be created in the shortest and most cost effective way to the customer.”

Happy International Women’s Day to all of the strong women out there. We support you.

01/07/2022

Meet Guruduth Banavar, Chief Technology Officer & Head of AI Discovery!

Guru is driven to develop and apply deep science and technology innovations to solve the big challenges of humanity, especially in health and education. He founded many successful initiatives, and is best known for his work on Host/Microbe Molecular Data Analysis, IBM Watson AI Systems, Smarter Cities, Services Innovation, Mobile Computing, and Distributed Systems.

Guru is the founding CTO of Viome Inc, where he leads AI and co-leads clinical research. Guru’s focus is on analyzing large host-microbiome gene expression datasets, discovering biomarkers, and identifying therapeutic targets from clinical research studies targeting metabolic, gastrointestinal, autoimmune, and neurological disorders, as well as cancer. He led the development of a first-of-a-kind saliva-based early detection system for oral and throat cancers using host/microbiome gene expression for Viome, which has received FDA’s designation as a breakthrough device.

"The oral cancer diagnostic is a first-of-a-kind proof of concept that showcases the power of the ViOS platform, and establishes a repeatable method for rapidly developing and validating novel diagnostics and therapeutics. We are happy to make this cutting edge platform available to the scientific community." - Guru Banavar

12/21/2021

Are you a life science researcher interested in a GRANT for state-of-the-art molecular data analysis? Viome Life Sciences has opened up our ViOS platform, and is offering grants to help translate research into clinical applications, devising new therapies and developing more effective diagnostics and companion diagnostics.

Learn more about our Grants Program and apply here:

Viome's science arm, Viome Life Sciences, focuses on developing consumer-friendly tests, offering research grants and collaborating with world class scientists and clinicians.

12/17/2021

Science alert! Viome published a peer-reviewed paper on a saliva-based diagnostic for oral cancer in NPJ Genomic Medicine. This paper demonstrates the power of Viome's platform to find disease signatures from human-microbiome interactions and this study is the first initiative of the Viome Systems Biology Discovery Platform, called ViOS™ that translates research collaboration and scientific discoveries into clinical tools that can improve and save lives.

Viome intends to repeat this AI-powered metatranscriptomic approach to identify disease & precursor states for many life-threatening conditions and chronic diseases.

Read more: https://lnkd.in/gpw7R245

Additionally, his newly published study marks the first significant results since the platform has been opened up to leading researchers from institutions around the world. Our Grants Program helps in the translation of research into commercial products with clinical utility, devising new therapies and developing more accurate diagnostics and companion diagnostics.

Learn more about our Grants program here: https://lnkd.in/ghA3Ts7n

/PRNewswire/ -- Viome Life Sciences (VLS) announces the publication of a clinical study performed with leading researchers and clinicians for early detection...

12/15/2021

We officially opened our state-of-the-art clinical laboratory in Bothell, WA!

Our lab is the only lab that uses clinically validated, direct-to-consumer, metatranscriptomic (unbiased RNA sequencing) analysis of stool, blood, and (soon) saliva samples. The labs support our clinical research activities and analyze customer samples that arrive from 93+ countries!

Our entire discovery platform (Viomega) is open access, and available to any clinician or researcher. Applications for accessing Viomega can be submitted here:
https://buff.ly/30lCsie

12/14/2021

Meet Dr. Emmanuel Hanon, our Global Head of Research & Development!

As global head of R&D for the vaccine group at GSK, Dr. Hanon oversaw teams across 50 countries dedicated to delivering discovery, development, and management activities for the company's vaccine efforts. Dr. Hanon was responsible for the shared science and technology platforms supporting the entire vaccine business, managing technical development, clinical immunology, and preclinical stages of vaccine developments.

We are so lucky to have him with us. Say hello! https://buff.ly/3IJK0Ne

12/08/2021

Meet Dr. Momo Vuyisich, our CSO!

“Before founding Viome, I worked for 12 years as a scientist at Los Alamos National Laboratory (LANL), where I was the leader of the Applied Genomics team. My team's research focused on developing and applying modern genomics to the areas of gut microbiomes, host-pathogen interactions, microbial interspecies interactions, pathogen detection, cancer biology, toxicology, infectious diseases, antibiotic resistance, forensics, etc. I also helped set up several turn-key genome centers in Africa and Asia, and provided complete staff training in laboratory methods and bioinformatic analyses.”